Cargando…

Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control

Diabetes mellitus and the associated complications represent a global burden on human health and economics. Cardiovascular diseases are the leading cause of death in diabetic patients, who have a 2–5 times higher risk of developing heart failure than age-matched non-diabetic patients, independent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Borghetti, Giulia, von Lewinski, Dirk, Eaton, Deborah M., Sourij, Harald, Houser, Steven R., Wallner, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218509/
https://www.ncbi.nlm.nih.gov/pubmed/30425649
http://dx.doi.org/10.3389/fphys.2018.01514
_version_ 1783368466407882752
author Borghetti, Giulia
von Lewinski, Dirk
Eaton, Deborah M.
Sourij, Harald
Houser, Steven R.
Wallner, Markus
author_facet Borghetti, Giulia
von Lewinski, Dirk
Eaton, Deborah M.
Sourij, Harald
Houser, Steven R.
Wallner, Markus
author_sort Borghetti, Giulia
collection PubMed
description Diabetes mellitus and the associated complications represent a global burden on human health and economics. Cardiovascular diseases are the leading cause of death in diabetic patients, who have a 2–5 times higher risk of developing heart failure than age-matched non-diabetic patients, independent of other comorbidities. Diabetic cardiomyopathy is defined as the presence of abnormal cardiac structure and performance in the absence of other cardiac risk factors, such coronary artery disease, hypertension, and significant valvular disease. Hyperglycemia, hyperinsulinemia, and insulin resistance mediate the pathological remodeling of the heart, characterized by left ventricle concentric hypertrophy and perivascular and interstitial fibrosis leading to diastolic dysfunction. A change in the metabolic status, impaired calcium homeostasis and energy production, increased inflammation and oxidative stress, as well as an accumulation of advanced glycation end products are among the mechanisms implicated in the pathogenesis of diabetic cardiomyopathy. Despite a growing interest in the pathophysiology of diabetic cardiomyopathy, there are no specific guidelines for diagnosing patients or structuring a treatment strategy in clinical practice. Anti-hyperglycemic drugs are crucial in the management of diabetes by effectively reducing microvascular complications, preventing renal failure, retinopathy, and nerve damage. Interestingly, several drugs currently in use can improve cardiac health beyond their ability to control glycemia. GLP-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors have been shown to have a beneficial effect on the cardiovascular system through a direct effect on myocardium, beyond their ability to lower blood glucose levels. In recent years, great improvements have been made toward the possibility of modulating the expression of specific cardiac genes or non-coding RNAs in vivo for therapeutic purpose, opening up the possibility to regulate the expression of key players in the development/progression of diabetic cardiomyopathy. This review summarizes the pathogenesis of diabetic cardiomyopathy, with particular focus on structural and molecular abnormalities occurring during its progression, as well as both current and potential future therapies.
format Online
Article
Text
id pubmed-6218509
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62185092018-11-13 Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control Borghetti, Giulia von Lewinski, Dirk Eaton, Deborah M. Sourij, Harald Houser, Steven R. Wallner, Markus Front Physiol Physiology Diabetes mellitus and the associated complications represent a global burden on human health and economics. Cardiovascular diseases are the leading cause of death in diabetic patients, who have a 2–5 times higher risk of developing heart failure than age-matched non-diabetic patients, independent of other comorbidities. Diabetic cardiomyopathy is defined as the presence of abnormal cardiac structure and performance in the absence of other cardiac risk factors, such coronary artery disease, hypertension, and significant valvular disease. Hyperglycemia, hyperinsulinemia, and insulin resistance mediate the pathological remodeling of the heart, characterized by left ventricle concentric hypertrophy and perivascular and interstitial fibrosis leading to diastolic dysfunction. A change in the metabolic status, impaired calcium homeostasis and energy production, increased inflammation and oxidative stress, as well as an accumulation of advanced glycation end products are among the mechanisms implicated in the pathogenesis of diabetic cardiomyopathy. Despite a growing interest in the pathophysiology of diabetic cardiomyopathy, there are no specific guidelines for diagnosing patients or structuring a treatment strategy in clinical practice. Anti-hyperglycemic drugs are crucial in the management of diabetes by effectively reducing microvascular complications, preventing renal failure, retinopathy, and nerve damage. Interestingly, several drugs currently in use can improve cardiac health beyond their ability to control glycemia. GLP-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors have been shown to have a beneficial effect on the cardiovascular system through a direct effect on myocardium, beyond their ability to lower blood glucose levels. In recent years, great improvements have been made toward the possibility of modulating the expression of specific cardiac genes or non-coding RNAs in vivo for therapeutic purpose, opening up the possibility to regulate the expression of key players in the development/progression of diabetic cardiomyopathy. This review summarizes the pathogenesis of diabetic cardiomyopathy, with particular focus on structural and molecular abnormalities occurring during its progression, as well as both current and potential future therapies. Frontiers Media S.A. 2018-10-30 /pmc/articles/PMC6218509/ /pubmed/30425649 http://dx.doi.org/10.3389/fphys.2018.01514 Text en Copyright © 2018 Borghetti, von Lewinski, Eaton, Sourij, Houser and Wallner. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Borghetti, Giulia
von Lewinski, Dirk
Eaton, Deborah M.
Sourij, Harald
Houser, Steven R.
Wallner, Markus
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
title Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
title_full Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
title_fullStr Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
title_full_unstemmed Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
title_short Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
title_sort diabetic cardiomyopathy: current and future therapies. beyond glycemic control
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218509/
https://www.ncbi.nlm.nih.gov/pubmed/30425649
http://dx.doi.org/10.3389/fphys.2018.01514
work_keys_str_mv AT borghettigiulia diabeticcardiomyopathycurrentandfuturetherapiesbeyondglycemiccontrol
AT vonlewinskidirk diabeticcardiomyopathycurrentandfuturetherapiesbeyondglycemiccontrol
AT eatondeborahm diabeticcardiomyopathycurrentandfuturetherapiesbeyondglycemiccontrol
AT sourijharald diabeticcardiomyopathycurrentandfuturetherapiesbeyondglycemiccontrol
AT houserstevenr diabeticcardiomyopathycurrentandfuturetherapiesbeyondglycemiccontrol
AT wallnermarkus diabeticcardiomyopathycurrentandfuturetherapiesbeyondglycemiccontrol